Glycogen Synthase Kinase 3β Inhibitor Delivered by Chitosan Nanocapsules Promotes Safe, Fast, and Efficient Activation of Wnt Signaling <i>In Vivo</i>

Ambrosone, Alfredo; Matteis, Laura De; Serrano‐Sevilla, Inés; Tortiglione, Claudia; Fuente, Jesús M. de la

doi:10.1021/acsbiomaterials.9b01820

Cited by 10 publications

(4 citation statements)

References 70 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many efforts have been made to identify new anticancer candidates. Biopolymers (CS) as carrier systems for pharmaceuticals and mucoadhesive formulations have been employed to promote sustainability in the pharmaceutical area 56 and because of their low toxicity, biodegradability, and colloidal stability in aqueous solutions 57 , 58 .…”

Section: Resultsmentioning

confidence: 99%

Fabrication and characterization of unique sustain modified chitosan nanoparticles for biomedical applications

Ahmed,

Mohamed,

Ahmed

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Chitosan (CS) is a biopolymer that offers a wide range in biomedical applications due to its biocompatibility, biodegradability, low toxicity and antimicrobial activity. Syringaldehyde (1) is a naturally occurring organic compound characterized by its use in multiple fields such as pharmaceuticals, food, cosmetics, textiles and biological applications. Herein, development of chitosan derivative with physicochemical and anticancer properties via Schiff base formation from the reaction of chitosan with sustainable eco-friendly syringaldehyde yielded the (CS-1) derivative. Moreover, in the presence of polyethylene glycol diglycidyl ether (PEGDGE) or sodium tripolyphosphate (TPP) as crosslinkers gave chitosan derivatives (CS-2) and (CS-3NPs) respectively. The chemical structures of the new chitosan derivatives were confirmed using different tools. (CS-3NPs) nanoparticle showed improvement in crystallinity, and (CS-2) derivative revealed the highest thermal stability compared to virgin chitosan. The cytotoxicity activity of chitosan and its derivatives were evaluated against HeLa (human cervical carcinoma) and HEp-2 (Human Larynx carcinoma) cell lines. The highest cytotoxicity activity was exhibited by (CS-3NPs) compared to virgin chitosan against HeLa cell growth inhibition and apoptosis of 90.38 ± 1.46% and 30.3% respectively and IC50 of 108.01 ± 3.94 µg/ml. From the above results, it can be concluded that chitosan nanoparticle (CS-3NPs) has good therapeutic value as a potential antitumor agent against the HeLa cancer cell line.

show abstract

Section: Resultsmentioning

confidence: 99%

Fabrication and characterization of unique sustain modified chitosan nanoparticles for biomedical applications

Ahmed,

Mohamed,

Ahmed

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Many efforts have been made to identify new anticancer candidates. Biopolymers (CS) as carrier systems for pharmaceuticals and mucoadhesive formulations have been employed to promote sustainability in the pharmaceutical area 52 and because of their low toxicity, biodegradability, and colloidal stability in aqueous solutions 53,54 .…”

Section: Evaluation Of Antitumor Activitymentioning

confidence: 99%

Unique Sustain Anticancer Modified Chitosan Nanoparticle: Fabrication and Characterization

Ahmed,

Mohamed,

Ahmed

et al. 2024

Preprint

View full text Add to dashboard Cite

Chitosan (CS) is a biopolymer offers a wide range in biomedical applications due to its biocompatibility, biodegradability, low toxicity and antimicrobial activity. Syringaldehyde (1) is naturally organic compound characterized by its uses in multiple fields such as pharmaceuticals, food, cosmetics, textiles and biological applications. Herein, development of chitosan physicochemical and anticancer properties via Schiff base formation from the reaction of chitosan with sustainable eco-friendly syringaldehyde yielded (CS-1) derivative. Moreover, in presence of polyethylene glycol diglycidyl ether (PEGDGE) or sodium tripolyphosphate (TPP) as crosslinkers gave chitosan derivatives (CS-2) and (CS-3NPs) respectively. The chemical structures of new chitosan derivatives are confirmed using different tools. (CS-3NPs) nanoparticle showed improvement in crystallinity, and (CS-2) derivative revealed the highest thermal stability compared to virgin chitosan. The cytotoxicity activity of chitosan and its derivatives is evaluated against HeLa (human cervical carcinoma) and HEp-2 (Human Larynx carcinoma) cell lines. The highest cytotoxicity activity is exhibited by (CS-3NPs) compared to virgin chitosan against HeLa cell growth inhibition and apoptosis of 90.38±1.46% and 30.3% respectively and IC50 of 108.01±3.94 µg/ml. From the above results, it can be concluded that chitosan nanoparticle (CS-3NPs) might be good therapeutic value as a potential antitumor agent against HeLa cancer cell line.

show abstract

“…They also studied the characteristics of the intracellular delivery with Nile red-loaded NPs. Their methodology resulted in a more efficient manner of activating Wnt pathway than free alsterpaullone at the same concentration (Ambrosone et al, 2020). Similarly, Montero et al developed chitosan-BSA NPs and studied their potential as vehicles with different combinations, demonstrating their potential for drug delivery (Montero et al, 2019).…”

Section: Polysaccharide Nanoparticlesmentioning

confidence: 99%

Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale

Fernández-Gómez

Aranda

Tosat‐Bitrián

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The new and unique possibilities that nanomaterials offer have greatly impacted biomedicine, from the treatment and diagnosis of diseases, to the specific and optimized delivery of therapeutic agents. Technological advances in the synthesis, characterization, standardization, and therapeutic performance of nanoparticles have enabled the approval of several nanomedicines and novel applications. Discoveries continue to rise exponentially in all disease areas, from cancer to neurodegenerative diseases. In Spain, there is a substantial net of researchers involved in the development of nanodiagnostics and nanomedicines. In this review, we summarize the state of the art of nanotechnology, focusing on nanoparticles, for the treatment of diseases in Spain (2017–2022), and give a perspective on the future trends and direction that nanomedicine research is taking.

show abstract

Glycogen Synthase Kinase 3β Inhibitor Delivered by Chitosan Nanocapsules Promotes Safe, Fast, and Efficient Activation of Wnt Signaling In Vivo

Cited by 10 publications

References 70 publications

Fabrication and characterization of unique sustain modified chitosan nanoparticles for biomedical applications

Fabrication and characterization of unique sustain modified chitosan nanoparticles for biomedical applications

Unique Sustain Anticancer Modified Chitosan Nanoparticle: Fabrication and Characterization

Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale

Contact Info

Product

Resources

About